Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04251533
Title	Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (EPIK-B3)
Acronym	EPIK-B3
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	triple-receptor negative breast cancer
Therapies	Alpelisib + Nab-paclitaxel Nab-paclitaxel
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| SVN \| SVK \| POL \| NOR \| ITA \| ISR \| HUN \| HRV \| GBR \| FRA \| ESP \| DEU \| CHE \| BRA \| BGR \| AUT \| AUS \| ARG